PESTICIDE RESIDUES IN FOOD - 1984 Sponsored jointly by FAO and WHO EVALUATIONS 1984 The monographs Data and recommendations of the joint meeting of the FAO Panel of Experts on Pesticide Residues in Food and the Environment and the WHO Expert Group on Pesticide Residues Rome, 24 September - 3 October 1984 Food and Agriculture Organization of the United Nations Rome 1985 DEMETON-S-METHYL SULFONE EVALUATION FOR ACCEPTABLE DAILY INTAKE BIOCHEMICAL ASPECTS Absorption, Distribution and Excretion Absorption, distribution and excretion of radioactivity were assayed in male Sprague-Dawley rats given single oral doses of 0.1, 0.5, 5 or 10 mg/kg or intravenous doses of 0.5 or 1 mg/kg of 14C-demeton-S-methyl sulfone. Additional female rats were given a single oral dose of 0.5 mg/kg. The test material was very rapidly and nearly completely absorbed following oral administration. More than 50 percent of the administered radioactivity was eliminated in about three hours and approximately 90 percent within about 10 hours following an oral dose of 0.5 or 5 mg/kg. Within 48 hours, radioactivity excreted in the urine accounted for 97-99 percent of the administered dose. Faeces accounted for 0.6-2.5 percent and expired air for less than 0.1 percent. Radioactivity remaining in the body was about 50 percent of the administered dose at two hours (about 50 percent having been already excreted at that time), about 1 percent at 24 hours, 0.7 percent at 48 hours and 0.27 percent at 10 days. Total recovered radioactivity in experiments averaged 90-110 percent. Recovery percentages in excreta were largely independent of dose level, route of administration and sex of the animal. Rates of elimination were dose proportional. In a separate experiment in which 0.5 mg/kg of 14C-demeton-S-methyl sulfone was intraduodenally administered to male rats with bile duct fistulas, about 4 percent of the administered radioactivity was excreted in the bile within 24 hours. Blood levels of radioactivity peaked at about 1 hour following oral administration of 5 mg/kg of the test material. From 0 to 6 hours post-dosing, the blood half-life was calculated to be about two hours, from 6 to 24 hours to be about 7 hours and after 24 hours to be considerably longer. Nearly all the radioactivity in the blood after 24 hours was accounted for by a high retention in erythrocytes which had considerably higher levels of radioactivity than other organs and tissues for up to ten days. Serum levels after 24 hours were quite low compared to erythrocytes and at 10 days were negligible. Distribution of radioactivity in various body organs and tissues were relatively uniform at two hours. Radioactivity did not concentrate in fat tissue or in the reticuloendothelial system (liver, spleen, bone marrow). By day two post-administration, radioactivity in most organs and tissues, except blood and erythrocytes, had dropped 75 fold. At day 10, radioactivity was nearly undetectable in the majority of organs and tissues except for lungs, blood and erythrocytes. In a separate experiment, whole-body autoradiography confirmed previous findings regarding distribution of radioactivity in body tissues, but also indicated some localized accumulation or radioactivity in the pineal gland and in some glands of the genital tract (Cowper's gland, seminal vescicle, accessory genital gland) (Weber, Patzschke and Wegner, 1978). Biotransformation Urine samples from male Sprague-Dawley rats given single oral administrations of 10 mg/kg of 14C-demeton-S-methyl sulfone were subjected to chemical analyses to identify and quantitate unchanged parent and metabolites. Zero to 8 hour and 8 to 24 hour urine samples used in this study were collected from four rats utilized in the study by Weber, Patzschke and Wegner in 1978. Approximately 90 percent of the administered radioactivity was recovered in the urine within eight hours and an additional 5 percent by 24 hours. Compounds were separated by thin layer chromatography and high-pressure liquid chromatography. Radioactivity was assayed by several counting techniques. Mass spectroscopy in conjunction with chemical synthesis was used to identify the main metabolite. This metabolite was determined to be methyl sulfinyl-2-ethyl sulfonyl ethane, which is presumably formed after cleavage of the O-methyl-phosphoric ester group, methylation and sulfoxidation of the methyl thioether group. Identities and percentages of total radioactivity in the 0-8 hour urine sample were as follows: demeton-S-methyl sulfone (unchanged parent compound), 30 percent O-demethyl-demeton-S-methyl sulfone, 20 percent; and methyl sulfinyl-2-ethyl sulfonyl ethane, 40 percent. The remaining unknown metabolites each accounted for less than 5 percent of the total radioactivity. The 8-24 hour urine samples, from the same rats as the 0-8 hour sample, showed the same distribution of parent compound and metabolites, but with a considerably lower radioactivity content (Ecker and Wunsche, 1980). Effects on Enzymes and Other Biochemical Parameters Aqueous solutions of technical grade demeton-S-methyl sulfone were dermally applied on foam rubber pads to the shorn backs of giant Chinchilla rabbits for single 24 hour exposures at dosage levels of 500 and 50 mg/kg/day. At 500 mg/kg, plasma and erythrocyte cholinesterase activities were decreased for at least seven days. At 50 mg/kg, cholinesterase activities were unaffected. When dermally applied for four consecutive exposures of 24 hours each at dosage levels of 50 and 10 mg/kg/day, a decrease in plasma cholinesterase activity persisted at least five days after the end of treatment. A decrease in erythrocyte cholinesterase activity, present at the end of treatment, was not as pronounced, and recovered to the control level by five days after the end of treatment. When dermally applied to five male and five female rabbits per group for 14 consecutive exposures of 24 hours each at dosage levels of 0 (control) and 2.5 mg/kg/day, plasma and erythrocyte cholinesterase activities were unaffected by the treatments. In addition, no differences were observed between treated and control animals in appearance, behaviour or body weights. Minimal haematology, clinical chemistry and urinalysis laboratory determinations also indicated no differences between treated and control animals (Kimmerle and Solmecke, 1972). TOXICOLOGICAL STUDIES Acute Toxicity Acute oral LD50s were determined for seven production batches of demeton-S-methyl sulfone (E 158, M 3/158, purity approximately 97.7 percent). In studies on non-fasted male rats, LD50s ranged from 37 to 44 mg/kg. In another study on fasted male rats, the LD50 was 23 mg/kg (Mihail, 1980; Mihail, 1981). Short-term studies Dog Demeton-S-methyl sulfone (e 158, M 3/158, assayed purity 100.3 percent) was incorporated in feed at concentrations of 0 (control), 1, 5 and 25 ppm and presented to 17-21 week old thoroughbred Beagle dogs for 13 weeks. Based on diet analyses, food consumption and body weights determined during the study, the mean dosage levels were calculated to be 0 (control), 0.3, 1.5 and 7.4 mg/kg/day. Each group consisted of four male and four female dogs. Appearance and behaviour were checked several times per day. Body weights were recorded weekly. Examinations for reflexes and ophthalmoscopic effects were conducted before and during the study at 6 and 12 weeks. Standard haematology, clinical chemistry and urinalysis examinations were performed on the same days. Plasma and erythrocyte cholinesterase activities were performed before and during the study at weeks 2, 4, 7, 10 and 13. Brain cholinesterase activity was determined at termination of the study. Gross necropsies were performed on all dogs. Organ weights were recorded for brain, heart, lung, liver, spleen, kidneys, thymus, pancreas, testes, prostate, ovaries, pituitary, thyroid and adrenals. Histopathological examination was performed on 13 major organs and tissues of all dogs. Thirteen additional organs and tissues were microscopically examined only from dogs in the control and 25 ppm groups. One 25 ppm female dog was sacrificed in week 11 of the study due to a severe acute infection which developed in its right chin during week 10 and which increased rapidly in size to "child's fist size". The large abscess prevented the dog from eating. This animal's death was not attributed to the test material. There were no other mortalities during the study. Appearance and behaviour were normal in all dogs at all times during the study. Reflex and ophthalmoscopic examinations were negative. Food and water consumptions were equivalent in treated and control male and female groups respectively. Mean body weights were comparable at all times during the study between treated and control male and female groups respectively. Haematology, clinical chemistry and urinalysis examinations indicated no alterations attributable to the test material. Plasma cholinesterase activity levels were significantly decreased in 25 ppm male dogs from week two to termination of the study and in 25 ppm female dogs from week 7 to termination of the study. Decreases in erythrocyte cholinesterase activity were more pronounced than in plasma. Statistically significant decreases were reported in both male and female 25 ppm groups from week 4 to termination of the study and also in 5 ppm male dogs from week 9 to termination of the study. Brain cholinesterase activity was unaffected in male dogs, but was significantly decreased in 25 ppm female dogs. Gross necropsies revealed a few minor alterations commonly seen in dogs of comparable ages. Organ weights and organ/body weight ratios suggested possibly increased thyroid weights in 25 ppm male dogs, possibly increased heart weights in 25 ppm female dogs. None of the organ weight changes, however, were likely to be biologically meaningful since no supporting histopathological lesions were observed. Microscopic examination of organs and tissues indicated no lesions attributable to the test material. Observed lesions were of types often seen in dogs of comparable ages and were randomly observed in all groups. The cholinesterase NOEL for this study is 1.0 ppm (equal to 0.3 mg/kg/day). The NOEL for somatic effects is 25 ppm (equal to 7.4 mg/kg/day) (Hoffman, Luckhaus and Dycka, 1975). Special Studies on Teratogenicity Rat Previously inseminated BAY:FB 30 strain rats were given orally by stomach tube on days 6 to 15 of gestation E 158 (demeton-S-methyl sulfone, purity 97.7 percent) at dosage levels of 0 (control), 0.3, 1.0 and 3.0 mg/kg/day. Each group contained 25 rats. Dams were observed daily for appearance and behaviour and were weighed several times during gestation. Following caesarean section on gestation day 20, numbers of implantations, implantation losses and live and dead foetuses were determined. Placentas were weighed. Foetuses were weighed, sexed and examined for external malformations. Approximately 30 percent of the foetuses were examined for visceral malformations by a modification of Wilson's technique and the remainder for skeletal alterations by the Alizarin Red S technique. There were no mortalities or abnormalities in appearance or behaviour noted in the control, 0.3 or 1.0 mg/kg/day dosage level groups. In the 3.0 mg/kg/day group, all dams showed toxic effects consisting of tremor, high respiration rate, protusio bulbi, passing of hard stools and/or hollow flanks. Mean body weights were significantly (p < 0.01) decreased in 1.0 mg/kg/day dams during gestation days 6 to 15 and in 3.0 mg/kg/day dams during gestation days 6 to 15 and also during the entire gestation period. The numbers of dams delivering litters were 21, 22, 19 and 22 for the control, low-, mid- and high-dosage groups respectively. No significant differences between control and treated groups were noted for numbers of implantations, implantation losses or live and dead foetuses. Placenta weights, foetal weights and foetal sex ratios in treated groups were comparable to those of the control group. Numbers of stunted foetuses (less than 3 grams) were 0/248, 0/279, 1/234 and 6/262 for the control, low-, mid- and high-dosage groups respectively. In units of mean numbers of stunted foetuses per litter, the respective incidences were 0.00, 0.00, 0.05 and 0.27. This malformation was observed in 1/19 litters in the 1.0 mg/kg/day group and in 3/22 litters in the 3.0 mg/kg/day group. Historical control data presented in the study report expressed as numbers of dams with stunted foetuses in each of 30 control groups, indicated the incidence in this study (up to 3/22) to be within the normal range of variation. No historical control data was presented, however, in which numbers of affected foetuses were indicated. [Note - in view of the causative relationship between oxydemeton-methyl and this same malformation in the study by Machemer, 1979, the increased incidence of stunted foetuses in this study should be considered as possibly related to the test material]. Other visceral and skeletal malformations in foetuses in this study were few and not related to the test material. In particular, there were no hypoplasias of the cerebral hemisphere noted for any of the foetuses in this study. [Note - there was a causative relationship established between oxydemeton-methyl and this malformation in the study by Machemer, 1979]. The numbers of foetuses with skeletal variations in treated groups were comparable to control levels (Roetz, 1982). Rabbit E 158 (demeton-S-methyl sulfone, purity 97.7 percent) was administered by gavage to mated Chinchilla Hybrid rabbits on gestation days 6 to 18 at dosage levels of 0 (control), 0.5, 1.0 and 2.0 mg/kg/day. Dosage levels were selected after a preliminary study in which animals similarly treated with 3.0 and 6.0 mg/kg/day displayed diarrhoea, decreased body weights, decreased food consumption and mortalities. Each group consisted of 16 rabbits. The dams were observed two times daily for mortality, appearance and behaviour. Body weights were recorded daily and food consumption was determined six times during the study. Caesarean sections were performed on gestation day 28. Dams were necropsied for gross changes and special attention was given to ovaries and particularly to uterine contents. All foetuses were counted, weighed, sexed, inspected externally and then subjected to thorough and comprehensive visceral and skeletal examinations. There were no mortalities. Appearance and behaviour were normal in all animals in all groups at all times. There were no meaningful differences in body weights or food consumption between treated groups and the control group throughout the entire study. The numbers of litters examined were 15, 15, 16 and 16 in the control, low-, mid- and high-dosage groups respectively. One animal in the control group and one in the 0.5 mg/kg/day group had no implantations. There were no abortions. Regarding reproductive parameters, there were no relevant differences between test and control groups in the numbers of implantations per dam, pre-implantation losses, post-implantation losses, resorptions, living and dead foetuses or sex ratios. The numbers of foetuses examined were 134, 120, 140 and 143 in the control, low-, mid- and high-dosage groups respectively. There were no relevant differences in foetal body weights. External and visceral examinations revealed no findings in any group. Similarly, skeletal examinations revealed no relevant findings in any group. Isolated instances of irregular ossified sternebrae and other minor skeletal variations occurred randomly across all groups. No embryotoxic or teratogenic potential was observed in the rabbits in this study at dosage levels up to 2.0 mg/kg/day (Becker, 1983). Special Studies on Mutagenicity For the results of mutagenicity studies see Table 1. Comments Demeton-S-methyl sulfone was rapidly and nearly completely absorbed in rats following oral administration. More than 50 percent of single doses was excreted within three hours and 90 percent within about ten hours. By 48 hours, only 0.7 percent remained in the body. Some binding to erythrocytes occurred for at least ten days. Excretion was almost entirely via the urine. Compounds identified in the urine were unchanged parent compound (30 percent), O-demethylated parent compound (20 percent) and methyl sulfinyl-2-ethyl sulfanyl ethane (40 percent). Two unknown metabolites each accounted for less than 5 percent. In a 13-week dietary feeding study in dogs, the NOEL for erythrocyte cholinesterase depression was 1 ppm (equal to 0.3 mg/kg/day), and for plasma and brain was 5 ppm (equal to 1.5 mg/kg/day). No other effects attributable to demeton-S-methyl sulfone were observed at dosage levels up to 25 ppm (equal to 7.4 mg/kg/day). In a teratology study on rats, the incidence of stunted foetuses was increased at the highest dosage level of 3.0 mg/kg/day. Although historical control data presented in the study report indicated the observed incidence to be within the normal range of variation, in view of the causative relationship between oxydemeton-methyl and this same malformation also in rats (Machemer, 1979), the increased incidence of stunted foetuses in this study should be considered as possibly related to the test material. At the same dosage level, maternal toxicity, including cholinergic signs of poisoning and decreased mean body weights, was also observed. A teratology study in rabbits at dosage levels up to 2.0 mg/kg/day did not demonstrate embryotoxic, foetotoxic or teratogenic effects. Mutagenicity studies on demeton-S-methyl sulfone were equivocal in a number of in vitro tests, but were negative in in vivo tests. FURTHER WORK OR INFORMATION NEEDED BEFORE AN ADI CAN BE ESTABLISHED Required: Reproduction study. Long-term feeding study in rodents. 6-month or longer feeding study in dogs. Desirable: Observations in humans. REFERENCES Becker, H. Embryotoxicity and teratogenicity study on E 158 1983 (Demeton-S-methyl-sulphon) in rabbits. Research and Consulting Company Ltd. Itingen, Switzerland. Report No. R. 2444. Submitted by Bayer AG to WHO. DeGraff, W.G. Mutagenicity evaluation of E 158 batch 808 108 117, 1983 Content 98.5% (Demeton-S-methylsulphon) in the reverse mutation induction assay with Saccharomyces cerevisiae strains S 138 and S 211 (Revised Final Report). Kensinton, MD. Litton Bionetics, Inc. LBI Project No. 20998, Report No. R 2417. Submitted by Bayer AG to WHO. Ecker, W. and Wunsche, C. Biotransformation of [ethylene-1-14C] 1980 Demeton-S-methyl sulphone (Metaisosystox-sulphone active ingredient) in rats. Bayer AG, Institute for Pharmacokinetics. PF Report No. 1485, Pharma Report No. 9604. Submitted by Bayer AG to WHO. Herbold, B. M 3/158 (E 158; Demeton-S-methylsulfon)/Dominant-Lethal 1980a Test an der männlichen Maus zur Prüfung auf mutagene Wirkung. Bayer AG, Institute for Toxicology. Report No. 9612. Submitted by Bayer AG to WHO (in German). Herbold, B. M 3/158 (E 158; Demeton-S-methylsulfon): 1980b Salmonella/Mikrosomen-Test zur Untersuchung auf punktmutagene Wirkung. Bayer AG, Institute for Toxicology. Report No. 9169. Submitted by Bayer AG to WHO (in German). Herbold, B. M 3/158 (eE 158; Demeton-S-methylsulfon): Mikronucleus- 1981 Test an der Maus zur Prüfung auf mutagene Wirkung. Bayer AG, Institute for Toxicology. No. 10261. Submitted by Bayer AG to WHO (in German). Hoffman, K., Luckhaus, G. and Dycka, J. M 3/158 (Metaisosystoxy- 1975 sulphone): subchronic toxicity study on dogs with administration in the feed (13 week study). Bayer AG, Institute for Toxicology. Report No. 5355. Submitted by Bayer AG to WHO. Kimmerle, G. and Solmecke, B. Metaisosystox-sulphone sub-acute dermal 1972 application to rabbits. Bayer AG, Institute for Toxicology. Report No. 3351. Submitted by Bayer AG to WHO. Machemer, L. R. 2170 (Oxydemeton-methyl; active ingredient of 1979 metasystox R): evaluation for embryotoxic and teratogenic effects in orally dosed rats. Bayer AG, Institute for Toxicology. Report No. 8436. Submitted by Bayer AG to WHO. Mihail, F. Determination of acute toxicity (LD50). Bayer AG, Institute 1980 for Toxicology. Submitted by Bayer AG to WHO Mihail, F. Determination of Acute Toxicity (LD50). Bayer AG, Institute 1981 for Toxicology. Submitted by Bayer AG to-WHO. Roetz, R. E 158 (Demeton-S-methylsulphon, Metaisosystox-sulphon): 1982 study for embryotoxic effects on the rat after oral administration. Bayer AG, Institute for Toxicology. Report No. 11234. Submitted by Bayer AG to WHO. Weber, H., Patzschke, K. and Wegner, L.A. [14C] Demeton-S-methyl- 1978 sulphone: Biokinetic studies on rats. Bayer AG, Institute for Pharmacokinetics. Report No. 7558. Submitted by Bayer AG to WHO.
See Also: Toxicological Abbreviations